Dated funding evidence

Sitryx Therapeutics

Series B · $39M / £32M · 2023-09-01

Reported round$39M / £32MSeries B

Company

2023-09-01Series B$39M / £32M

Resolved investor records

Investor links inherit this round’s named source and date. Resolved links use an exact canonical investor name; unresolved names remain unlinked.

SourceVC research snapshot; Live Chris T D1Date2023-09-01Matchfunding_id joined to resolved canonical companyStatepublished

Record fields

What the source states

Amounts, currency, stage and investor names are preserved as reported. No FX conversion, valuation inference or current-holding claim is added.

Round ID: FR-00598
Stage: Series B
Round name: Series B (described in source as 'additional financing' - letter not explicit)
Amount: $39M / £32M

Lead investors: Oxford Science Enterprises
Other investors: SV Health Investors, Eli Lilly, Sofinnova Partners, Longwood Fund, GSK
Source layers: VC research snapshot, Live Chris T D1
Snapshot: 2026-08-15

Named evidence

This page is published only when the record has a resolved company, disclosure date, round stage and at least one retained source URL.